Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(9 sites) China
Beijing Cancer Hospital, Beijing, Beijing Municipality Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality Henan Cancer Hospital, Zhengzhou, Henan The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan Hunan Cancer Hospital, Changsha, Hunan Jiang Su Province Hospital, Nanjing, Jiangsu Cancer Hospital of Shandong First Medical University, Jinan, Shandong ZhongShan Hospital Fudan University, Shanghai, Shanghai Municipality Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin Municipality